NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $1.44 -0.22 (-13.25%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Capstone Therapeutics Stock (NASDAQ:CAPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.6950-Day Range$1.36▼$1.9452-Week Range$1.29▼$16.18Volume177,609 shsAverage Volume90,559 shsMarket Capitalization$230.40 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Read More Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPS Stock News HeadlinesMichael ParkerJune 18, 2025 | latimes.comCapstone Holding Corp., Secures $1 Million Pangaea Stone Order in Expanding TerritoryJune 17, 2025 | finanznachrichten.deOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas. | InvestorPlace (Ad)Pinecrest, Florida Resident David Buitrago Completes Intensive Capstone Research ProjectJune 16, 2025 | msn.comA capstone projectJune 14, 2025 | yahoo.comCSM Honors 32 Leaders in 2025 Academy CeremonyJune 14, 2025 | msn.comCapstone Holding Corp. (J7W.F)June 12, 2025 | finance.yahoo.comStudents At NHTI, Concord’s Community College, Solve DNA Extraction ConundrumJune 10, 2025 | msn.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $2.40 on January 1st, 2025. Since then, CAPS shares have decreased by 40.0% and is now trading at $1.44. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an initial public offering (IPO) on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share. When does the company's lock-up period expire? Capstone Therapeutics's lock-up period expires on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its initial public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPS CIK887151 WebN/A Phone(708) 371-0660Fax602-286-5300Employees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.28 Current Ratio1.14 Quick Ratio0.47 Sales & Book Value Annual Sales$44.88 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value($19.40) per share Price / Book-0.07Miscellaneous Outstanding Shares160,000Free Float90,000Market Cap$230.40 thousand OptionableN/A Beta-0.80 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CAPS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.